Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 150 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Venetoclax in combination with bortezomib and dexamethasone for relapsed multiple myeloma - second line and beyond	Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2018	View \| Download
Venetoclax in combination with azacitidine for myelodysplastic syndrome	Azacitidine (Vidaza; CC-486) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Myelodysplastic syndrome (MDS)	Haematological Cancer and Lymphomas	2023	View \| Download
Venetoclax in combination with a hypomethylating agent or low dose cytarabine for newly diagnosed acute myeloid leukaemia	hypomethylating agent , Low-dose cytarabine , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2018	View \| Download
Venetoclax in addition to ibrutinib for relapsed mantle cell lymphoma – second-line and beyond	Ibrutinib (Imbruvica) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Mantle cell lymphoma	Haematological Cancer and Lymphomas	2020	View \| Download
Ublituximab in Combination with Ibrutinib for High Risk Chronic Lymphocytic Leukaemia	Ibrutinib (Imbruvica) , Ublituximab (TG-1101; LFB-R603)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2018	View \| Download
Ublituximab (TG-1101) in combination with umbralisib (TGR-1202) for chronic lymphocytic leukaemia	Ublituximab (TG-1101; LFB-R603) , Umbralisib (TGR-1202; RP-5264)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2017	View \| Download
Treosulfan in combination with Fludarabine for Malignant and Non-Malignant diseases - prior to stem cell transplantation	Fludarabine (fludarabine phosphate) , Treosulfan (Ovastat)	Acute myeloid leukaemia (AML) , Myelodysplastic syndrome (MDS)	Haematological Cancer and Lymphomas	2018	View \| Download
Tisagenlecleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma – second line	Tisagenlecleucel-T (Kymriah; CTL019)	B-cell non-Hodgkin lymphoma	Haematological Cancer and Lymphomas	2021	View \| Download
Tisagenlecleucel for relapsed or refractory follicular lymphoma	Tisagenlecleucel-T (Kymriah; CTL019)	Follicular lymphoma	Haematological Cancer and Lymphomas	2021	View \| Download
Teclistamab with daratumumab for previously treated relapsed or refractory multiple myeloma	Daratumumab (Darzalex; JNJ-54767414) , Teclistamab	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2022	View \| Download